CORDIS CROWNs 1997 WITH NEXT-GENERATION CORONARY STENT APPROVAL; FULL-SCALE U.S. LAUNCH BEGINS JAN. 1 THROUGH 100-PERSON DIRECT SALES FORCE
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Cordis unit began rolling out its Crown second-generation, balloon-expandable coronary stent Jan. 1, seeking to prolong its reign in an increasingly competitive market. Cordis will leverage its 100 person sales force so as to rapidly seed the market with its latest stent offering, parent J&J said Dec. 22 following FDA approval of the device on Dec. 19.
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.